3rd Quarter - Report — NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION (2017)

Firm

NATIONAL KIDNEY FOUNDATION

Client

NATIONAL KIDNEY FOUNDATION

Income

—

Expenses

$60,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2018 Appropriations for the Deptartment of Health and Human Services (NIH, CDC, HRSA);Food and Drug Administration; and Department of Veterans Affairs

Lobbyist	Covered position, as disclosed
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Health Issues HCR

Implementation of the Patient Protection and Affordable Care Act Repeal and Replace of ACA Initiatives to support early detection and management of Chronic Kidney Disease (H.R. 3867) Initiatives to increase and facilitate organ donation and transplantation, including H.R.1270 (Living Donor Protection Act) and build support for a companion bill in the Senate Support for H.R. 2644, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017

Lobbyist	Covered position, as disclosed
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA)

Bills named: H.R. 1270 (115th), H.R. 3867 (115th), H.R. 2644 (115th)

Medicare/Medicaid MMM

Comments on End Stage Renal Disease Program Prospective Payment System and Quality Incentive Program Comments on proposed updates to CMS Quality Payment Program Comments on Physician Fee Schedule and Diabetes Prevention Program

Lobbyist	Covered position, as disclosed
TONYA SAFFER	—

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.